Drugs / prosaptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00286377 | Sep 2003 → Dec 2004 | HIV infectious disease, peripheral nervous system disorder | Savient Pharmaceuticals | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | prosaptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00286377 ↗ |
| Known as | PRO | “OBJECTIVES: To examine the efficacy and safety of Prosaptide (PRO) for the treatment of painful HIV-associated sensory neuropathies (HIV-SN).” PMID 17653259 ↗ Jul 2007 |
| Route | Subcutaneous | “2, 4, 8, or 16 mg/d PRO or PBO administered via subcutaneous (SC) injection for six weeks.” PMID 17653259 ↗ Jul 2007 |